Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

11 يوليو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

09 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Half-year statement of IPSEN liquidity agreement - 2024 06 30

08 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 يوليو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

02 يوليو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

25 يونيو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

18 يونيو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 يونيو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10 يونيو 2024 15:54:20 بحسب Nasdaq GlobeNewswire

Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

07 يونيو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 يونيو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   

06 يونيو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    

05 يونيو 2024 01:00:00 بحسب Nasdaq GlobeNewswire

Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

03 يونيو 2024 00:00:00 بحسب Nasdaq GlobeNewswire

Ipsen announces the launch of an employee shareholding plan

30 مايو 2024 11:15:00 بحسب Nasdaq GlobeNewswire

Annual General Meeting of Ipsen S.A. held on 28 May 2024

28 مايو 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

28 مايو 2024 00:00:00 بحسب Nasdaq GlobeNewswire